InstalabLoading...
InstalabLoading...
Gonorrhea is one of the most common sexually transmitted infections, and most of the time it shows no symptoms. You can carry it in your throat, rectum, urethra, or cervix and feel completely fine, while it quietly causes inflammation, raises your risk of HIV transmission, and gets passed to partners. The only reliable way to know is to test.
NAAT (nucleic acid amplification test) for Neisseria gonorrhoeae detects fragments of the bacterium's DNA or RNA in a sample from the urethra, vagina, cervix, rectum, throat, or urine. It is the most sensitive test available and finds infections that older methods like culture routinely miss, especially at the throat and rectum.
The lab amplifies tiny amounts of gonococcal genetic material from your sample until it can be detected. Some platforms target bacterial DNA (such as the Roche cobas and SDA platforms), while others target RNA (such as the Aptima Combo 2 assay, which targets 16S ribosomal RNA, a structural component the bacteria need to make proteins). Both produce a positive or negative result, not a numerical score.
A positive result means gonococcal genetic material was detected at that site, which reflects an active infection. The test does not measure how severe the infection is or how long it has been present. It also cannot tell you whether the strain is resistant to antibiotics, which is why a culture may still be needed in some cases.
Gonorrhea infects mucous membranes, and a urine or genital sample only checks one of the places it can live. Throat and rectal infections are common, especially among men who have sex with men, and most of them produce no symptoms. If you only test urine or a genital swab, you can carry an active infection at another site without knowing it.
In a study of women reporting extragenital exposures, urogenital-only testing would have missed 30% of gonorrhea cases and 14% of chlamydia cases, with age 18 or younger being the strongest predictor of having an extragenital infection. Among female sex workers, genital-only testing would miss 60% of gonorrhea infections. Switching from culture to NAAT in clinics serving men who have sex with men more than doubled the number of pharyngeal and rectal infections detected.
Untreated gonorrhea can ascend from the lower genital tract and cause pelvic inflammatory disease, which is a leading cause of infertility, ectopic pregnancy, and chronic pelvic pain in women. In men, it can cause epididymitis and inflammation of the testicles. Rarely, the bacteria can spread through the bloodstream and cause joint infections or skin lesions.
Asymptomatic infections at the rectum and throat are reservoirs for ongoing transmission, and pharyngeal infections are also where antibiotic resistance most often emerges. Pregnant women with untreated gonorrhea can pass the infection to their newborn during delivery, which can cause eye infection and blindness if not prevented.
NAATs detect far more infections than culture, the older standard, while keeping false positives low at most sites. The exception is the throat, where commensal Neisseria species that normally live there can occasionally be mistaken for gonorrhea by some platforms.
The numbers below come from clinical evaluation studies, not from the assay running on your own sample. Real-world performance can vary by lab and platform.
| Sample Site | How Often It Catches True Infection | How Often It Correctly Clears Uninfected People |
|---|---|---|
| Urethral, cervical, vaginal, or urine | Roughly 95 to 100 out of 100 | Roughly 98 to 100 out of 100 |
| Rectal | Roughly 78 to 100 out of 100, far better than culture's 24 to 72 | Roughly 95 to 100 out of 100 |
| Throat | Roughly 72 to 100 out of 100, far better than culture's 41 to 65 | Usually 94 to 99 out of 100, but some older PCR platforms drop to 72 to 73 |
What this means for you: at the throat especially, the platform your lab uses matters. RNA-based assays like Aptima Combo 2 and dual-target platforms have higher specificity than older single-target PCR. If you test positive at the throat in a low-risk situation, a confirmatory test on a different platform is worth requesting before treatment.
You do not always need a clinician to swab you. Self-collected vaginal swabs perform similarly to clinician-collected cervical or urine samples. Self-collected rectal swabs from men who have sex with men are valid specimens. At-home extragenital self-collection has been shown to be non-inferior to swabs done in a clinic, and self-collection roughly doubles testing uptake compared to clinic-only options.
NAATs are accurate, but a few situations can produce results that don't match what's actually happening in your body.
This is not a chronic biomarker that you trend like cholesterol. A NAAT result is a yes-or-no snapshot of whether you have an active infection at the moment of testing. The serial testing question is about how often to screen, not how to interpret a number's trajectory.
If you are sexually active with new or multiple partners, screen at least annually at every site of exposure (urogenital plus throat and rectum if relevant). If you are at higher risk, including men who have sex with men, people on PrEP, or people with multiple recent partners, every 3 to 6 months is reasonable. Retest 3 months after any positive result to check for reinfection, which is common. Pregnant women should be tested at the first prenatal visit and again in the third trimester if at increased risk.
A positive NAAT means you should be treated promptly with the regimen recommended by current guidelines. The standard first-line treatment is a single intramuscular injection of ceftriaxone. Doxycycline is added if chlamydia coinfection has not been ruled out. Test-of-cure is recommended only for pharyngeal infections or if symptoms persist; reinfection screening at 3 months is more important than test-of-cure for most cases.
Because gonorrhea is reportable to public health authorities in most jurisdictions, your provider may need to notify partners or coordinate expedited partner therapy. Get tested for other sexually transmitted infections at the same time, including chlamydia (which is usually included in the same NAAT panel), HIV, and syphilis. If you have a positive throat result and have been treated, ask about a culture-based test-of-cure to confirm clearance and to support antibiotic resistance surveillance.
Evidence-backed interventions that affect your Neisseria Gonorrhoeae NAA level
Neisseria Gonorrhoeae NAA is best interpreted alongside these tests.